Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Comparative Pharmacokinetic Study of Hesperetin after Oral Administration in Normal and Hyperuricemia Rats by UPLC-MS/MS

Author(s): Kexin Li, Li Wei, Zhigang Han, Huarong Xiong, Fengmei Zhang, Xuwei Liu, Dezhang Zhao, Yongquan Pan and Wenli Han*

Volume 16, Issue 2, 2021

Published on: 02 July, 2020

Page: [155 - 161] Pages: 7

DOI: 10.2174/1574884715666200702120521

Price: $65

Abstract

Background: Hesperetin has antihyperuricemia activity, and the pharmacokinetic profiles of hesperetin may be altered by hyperuricemia. This study aimed to develop a highly sensitive and specific method for the determination of hesperetin in normal and hyperuricemia rats, and to compare pharmacokinetic profiles of hesperetin after oral administration between normal and hyperuricemia rats.

Methods: Sprague-Dawley (SD) rats were randomly divided into one normal group (group A) and four hyperuricemia groups (group B, C, D, and E). Groups A, B, C, and D received a single dose (9–81 mg/kg) of hesperetin on Day 28, respectively, while group E received multiple doses (27 mg/kg) of hesperetin once daily for 28 days. Blood samples were collected at 10 different time points post-dose, and hesperetin was determined by Ultra-high Performance Liquid Chromatography- tandem Mass Spectrometric (UPLC-MS/MS).

Results: Compared with normal condition of group A, hyperuricemia of group C induced 48.19% and 19.57% decreases in Cmax and CL/F, and resulted in 58.25% and 19.48% increases in Tmax and AUC0-t for hesperetin, respectively. After 28 days of hesperitin treatment, Cmax of group E was significantly elevated than that of group C (p < 0.05). Hesperetin exhibited nonlinear pharmacokinetic properties in the range of 9-81 mg/kg in hyperuricemia rats.

Conclusion: The pharmacokinetic parameters of hesperetin in hyperuricemia rats were reported for the first time. Intestinal injury may be ameliorated by hesperetin in hyperuricemia rats after 28 days’ treatment. These findings could provide more beneficial information to the mechanism and clinical applications of hesperetin.

Keywords: Hesperetin, hyperuricemia rat, intestinal impairments, pharmacokinetic, UPLC-MS/MS, flavanone.

« Previous Next »
Graphical Abstract

[1]
Bodduluru LN, Kasala ER, Barua CC, Karnam KC, Dahiya V, Ellutla M. Antiproliferative and antioxidant potential of hesperetin against benzo(a)pyrene-induced lung carcinogenesis in Swiss albino mice. Chem Biol Interact 2015; 242: 345-52.
[http://dx.doi.org/10.1016/j.cbi.2015.10.020] [PMID: 26546711]
[2]
Matsumoto H, Ikoma Y, Sugiura M, Yano M, Hasegawa Y. Identification and quantification of the conjugated metabolites derived from orally administered hesperidin in rat plasma. J Agric Food Chem 2004; 52(21): 6653-9.
[http://dx.doi.org/10.1021/jf0491411] [PMID: 15479036]
[3]
Polat FR, Karaboğa I. Immunohistochemical examination of anti-inflammatory and anti-apoptotic effects of hesperetin on trinitrobenzene sulfonic acid induced colitis in rats. Biotech Histochem 2019; 94(3): 151-8.
[http://dx.doi.org/10.1080/10520295.2018.1530454] [PMID: 30383440]
[4]
Yamamoto M, Jokura H, Hashizume K, et al. Hesperidin metabolite hesperetin-7-O-glucuronide, but not hesperetin-3′-O-glucuronide, exerts hypotensive, vasodilatory, and anti-inflammatory activities. Food Funct 2013; 4(9): 1346-51.
[http://dx.doi.org/10.1039/c3fo60030k] [PMID: 23831969]
[5]
Haidari F, Ali Keshavarz S, Reza Rashidi M, Mohammad Shahi M. Orange juice and hesperetin supplementation to hyperuricemic rats alter oxidative stress markers and xanthine oxidoreductase activity. J Clin Biochem Nutr 2009; 45(3): 285-91.
[http://dx.doi.org/10.3164/jcbn.09-15] [PMID: 19902018]
[6]
Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 2015; 33(9): 1729-41.
[http://dx.doi.org/10.1097/HJH.0000000000000701] [PMID: 26136207]
[7]
Weaver DJ Jr. Uric acid and progression of chronic kidney disease. Pediatr Nephrol 2019; 34(5): 801-9.
[http://dx.doi.org/10.1007/s00467-018-3979-2] [PMID: 29931555]
[8]
Jiao Q, Xu L, Jiang L, Jiang Y, Zhang J, Liu B. Metabolism study of hesperetin and hesperidin in rats by UHPLC-LTQ-Orbitrap MSn. Xenobiotica 2019; 50(11): 1311-22.
[9]
Wang M, Zhao J, Zhang N, Chen J. Astilbin improves potassium oxonate-induced hyperuricemia and kidney injury through regulating oxidative stress and inflammation response in mice. Biomed Pharmacother 2016; 83: 975-88.
[http://dx.doi.org/10.1016/j.biopha.2016.07.025] [PMID: 27522260]
[10]
Wang S, Fang Y, Yu X, Guo L, Zhang X, Xia D. The flavonoid-rich fraction from rhizomes of Smilax glabra Roxb. ameliorates renal oxidative stress and inflammation in uric acid nephropathy rats through promoting uric acid excretion. Biomed Pharmacother 2019; 111: 162-8.
[http://dx.doi.org/10.1016/j.biopha.2018.12.050] [PMID: 30579255]
[11]
Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The confirms trial. Arthritis Res Ther 2010; 12(2): R63.
[http://dx.doi.org/10.1186/ar2978] [PMID: 20370912]
[12]
Kohagura K, Tana T, Higa A, et al. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia. Hypertens Res 2016; 39(8): 593-7.
[http://dx.doi.org/10.1038/hr.2016.37]
[13]
Wang Y, Zhao M, Ye H, et al. Comparative pharmacokinetic study of the main components of cortex fraxini after oral administration in normal and hyperuricemic rats. Biomed Chromatogr 2017; 31(8): e3934.
[http://dx.doi.org/10.1002/bmc.3934] [PMID: 28084025]
[14]
Krogholm KS, Bredsdorff L, Knuthsen P, Haraldsdóttir J, Rasmussen SE. Relative bioavailability of the flavonoids quercetin, hesperetin and naringenin given simultaneously through diet. Eur J Clin Nutr 2010; 64(4): 432-5.
[http://dx.doi.org/10.1038/ejcn.2010.6] [PMID: 20125185]
[15]
Nishizawa K, Yoda N, Morokado F, Komori H, Nakanishi T, Tamai I. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia. PLoS One 2019; 14(4): e0214862.
[http://dx.doi.org/10.1371/journal.pone.0214862] [PMID: 30951542]
[16]
Liu K, Wang W, Guo BH, et al. Chemical evidence for potent xanthine oxidase inhibitory activity of ethyl acetate extract of Citrus aurantium L. dried immature fruits. Molecules 2016; 21(3): 302.
[http://dx.doi.org/10.3390/molecules21030302] [PMID: 26950105]
[17]
Tong L, Zhou D, Gao J, Zhu Y, Sun H, Bi K. Simultaneous determination of naringin, hesperidin, neohesperidin, naringenin and hesperetin of Fractus aurantii extract in rat plasma by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 2012; 58(2): 58-64.
[http://dx.doi.org/10.1016/j.jpba.2011.05.001] [PMID: 22018980]
[18]
Shen C, Qian Z, Chen R, et al. Single dose oral and intravenous pharmacokinetics and tissue distribution of a novel hesperetin derivative MTBH in rats. Eur J Drug Metab Pharmacokinet 2016; 41(6): 675-88.
[http://dx.doi.org/10.1007/s13318-015-0293-2] [PMID: 26254910]
[19]
Spanakis M, Kasmas S, Niopas I. Simultaneous determination of the flavonoid aglycones diosmetin and hesperetin in human plasma and urine by a validated GC/MS method: In vivo metabolic reduction of diosmetin to hesperetin. Biomed Chromatogr 2009; 23(2): 124-31.
[http://dx.doi.org/10.1002/bmc.1092] [PMID: 18850579]
[20]
Guo Y, Jiang Q, Gui D, Wang N. Chinese herbal formulas Si-Wu-Tang and Er-Miao-San synergistically ameliorated hyperuricemia and renal impairment in rats induced by adenine and potassium oxonate. Cell Physiol Biochem 2015; 37(4): 1491-502.
[http://dx.doi.org/10.1159/000438517] [PMID: 26509423]
[21]
International Conference on Harmonization (Q2R1): Validation of Analytical Procedures: Text and Methodology Geneva, Switzerland. 1996. Available at: https://www.gmp-compliance.org/files/guidemgr/Q2(R1).pdf
[22]
Liu Y, Xu F, Zhang Z, Song R, Tian Y. Simultaneous determination of naringenin and hesperetin in rats after oral administration of Da-Cheng-Qi decoction by high-performance liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2008; 22(7): 736-45.
[http://dx.doi.org/10.1002/bmc.991] [PMID: 18384064]
[23]
Gu PC, Wang L, Han M-N, et al. Comparative pharmacokinetic study of mangiferin in normal and alloxan-induced diabetic rats after oral and intravenous administration by UPLC-MS/MS. Pharmacology 2019; 103(1-2): 30-7.
[http://dx.doi.org/10.1159/000493364] [PMID: 30359985]
[24]
Xu D, Lv Q, Wang X, et al. Hyperuricemia is associated with impaired intestinal permeability in mice. Am J Physiol-Gastr L 2019; 317(4): G484-92.
[http://dx.doi.org/10.1152/ajpgi.00151.2019]
[25]
He W, Liu M, Li Y, et al. Flavonoids from Citrus aurantium ameliorate TNBS-induced ulcerative colitis through protecting colonic mucus layer integrity. Eur J Pharmacol 2019; 857: 172456.
[http://dx.doi.org/10.1016/j.ejphar.2019.172456] [PMID: 31220438]
[26]
Kang DH. Hyperuricemia and progression of chronic kidney disease: Role of phenotype transition of renal tubular and endothelial cells. Contrib Nephrol 2018; 192: 48-55.
[http://dx.doi.org/10.1159/000484278] [PMID: 29393109]
[27]
Meibohm B, Zhou H. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol 2012; 52(1)(Suppl.): 54S-62S.
[http://dx.doi.org/10.1177/0091270011413894] [PMID: 22232754]
[28]
Tappei T, Kimiyoshi I, Hirotaka M, et al. ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion. Nucleos Nucleot Nucl 2014; 33(4-6): 7.
[29]
Ogura J, Kuwayama K, Sasaki S, et al. Reactive oxygen species derived from xanthine oxidase interrupt dimerization of breast cancer resistance protein, resulting in suppression of uric acid excretion to the intestinal lumen. Biochem Pharmacol 2015; 97(1): 89-98.
[http://dx.doi.org/10.1016/j.bcp.2015.06.021] [PMID: 26119820]
[30]
Morris ME, Zhang S. Flavonoid-drug interactions: Effects of flavonoids on ABC transporters. Life Sci 2006; 78(18): 2116-30.
[http://dx.doi.org/10.1016/j.lfs.2005.12.003] [PMID: 16455109]
[31]
Brand W, van der Wel PA, Rein MJ, et al. Metabolism and transport of the citrus flavonoid hesperetin in Caco-2 cell monolayers. Drug Metab Dispos 2008; 36(9): 1794-802.
[http://dx.doi.org/10.1124/dmd.107.019943] [PMID: 18515333]
[32]
Lu X, Chen M, Shen J, Xu Y, Wu H. IL-1β functionally attenuates ABCG2 and PDZK1 expression in HK-2 cells partially through NF-ĸB activation. Cell Biol Int 2019; 43(3): 279-89.
[http://dx.doi.org/10.1002/cbin.11100] [PMID: 30632646]
[33]
Wang MX, Liu YL, Yang Y, Zhang DM, Kong LD. Nuciferine restores potassium oxonate-induced hyperuricemia and kidney inflammation in mice. Eur J Pharmacol 2015; 747: 59-70.
[http://dx.doi.org/10.1016/j.ejphar.2014.11.035] [PMID: 25499818]
[34]
Lee JT, Pao LH, Hsieh CD, Huang PW, Hu OYP. Development and validation of an LC-MS/MS method for simultaneous quantification of hesperidin and hesperetin in rat plasma for pharmacokinetic studies. Anal Methods 2017; 9(22): 3329-37.
[http://dx.doi.org/10.1039/C7AY00051K]
[35]
Kanaze FI, Bounartzi MI, Georgarakis M, Niopas I. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur J Clin Nutr 2007; 61(4): 472-7.
[http://dx.doi.org/10.1038/sj.ejcn.1602543] [PMID: 17047689]

Rights & Permissions Print Cite
Article Metrics
18
1
© 2024 Bentham Science Publishers | Privacy Policy